Manuel Valdebran1,2*- 1Department of Dermatology, Medical University of South Carolina, Charleston, SC, United States
- 2Department of Pediatrics, Medical University of South Carolina, Charleston, SC, United States
Editorial on the Research Topic
Advances in evaluation and management of hair loss disorders
Alopecia areata (AA) is a non-scarring hair loss disorder which, depending on the extent of the disease, presents with focal patches of hair loss; complete loss of scalp hair, known as alopecia totalis (AT); or complete loss of scalp, facial and body hair, known as alopecia universalis (AU) (1). Less commonly AA may present as a band-like area on occipitotemporal scalp called ophiasis or sparing temporal and lower occipital scalp called sisaipho (ophiasis spelled backward). There are tools to measure extent of involvement include the “severity of alopecia tool” (SALT) score which is calculated by measuring the percentage of hair loss in each of 3 areas of the scalp: vertex (40%), right profile (18%), left profile (18%), and posterior (24%) (2) and the alopecia density and extent (ALODEX) score which combines both extent and hair density, usually calculated with a tablet (3).
Approximately, 34–50% of patients with AA recover within a year without need of a treatment, however many patients experience relapsing or remitting disease, 10–35% of those progressing to either AT or AU (4).
AA affects 2% of the general population, disproportionately affecting young people with an incidence peaking 20–24 years of age (5); its incidence is higher in females than males. Interestingly, increasing number of cases are seen in certain areas of the globe such as in Central sub-Saharan Africa and Western Sub-Saharan Africa (6).
AA is not a simple cosmetic disease, it is a medical condition with substantial financial burden for patients who must deal with higher plans, pharmacy, and out of pocket expenditures (4). Mesinkovska et al. have shown that patients spend on average $2,000 per year in wigs, hair pieces and psychotherapy visits alone (7). AA decreases health related quality of life, in fact, globally, there is a burden of 7.5 years lost due to AA, with the highest burden in high income North America, followed by Southern Latin America (6). In fact, AA is associated with 70% lifetime prevalence of psychiatric disorders such as anxiety and major depression (8) and many as 78% of adolescents have at least 1 lifetime prevalence of psychiatric disorder (9). Patients consider AA as a daily challenge and burden, with most people rating AA as a moderate or serious burden. As a matter of fact, the burden is significant enough to spend on average 10.3 h per week concealing hair loss (10).
AA is associated with higher incidences of other autoimmune diseases such as thyroid disease, pernicious anemia, and celiac disease and other autoinflammatory disease such as atopic dermatitis, lupus erythematosus, psoriasis, asthma, and allergic rhinitis (6, 11).
Traditionally, therapies to fight this autoinflammatory process have included topical minoxidil, topical contact-sensitizing agents, topical and intralesional corticosteroids and oral medications such as methotrexate or cyclosporine, however, most of the time with incomplete response to treatment, high rate of relapse or limited use due to side effects (12).
In Jun 13, 2022, the FDA approved baricitinib, the first systemic medication for AA, 8 years after Craiglow reported a patient with AU who responded completely to tofacitinib (13). Baricitinib and tofacitinib belong to a pharmacological group called Janus kinase (JAK) inhibitors. JAK is a cytoplasmic tyrosine kinase involved in many different proinflammatory processes within the body (14). Human genetic surveys and gene expression investigations have demonstrated that pathways upstream of the Janus kinases (JAK) are often disrupted in AA (15, 16).
Zhang et al. (17), provide evidence on the effectiveness of oral tofacitinib and systemic corticosteroids alone or combined in patients with moderate-to-severe alopecia areata.
The study has several takeaway points as follows: (1) Non-responding patients to monotherapy alone, achieved SALT 50 after receiving combined therapy (systemic corticosteroids and tofacitinib). (2) All AT and AU patients achieved SALT 50 on combined treatment while 60% did on monotherapy alone. (3) AO subset of patients showed less favorable response to treatment overall (40% in the combined group and 50% in the systemic corticosteroids group).
In addition, investigators report that there were no thromboembolic events, malignancy, or severe infections. The most common infections consisted of nasopharyngitis and upper respiratory infections. Other frequent side effects to be considered were acneiform eruption seen in all groups, as well as weight gain seen in both systemic corticosteroids and combined group.
Lastly, no hepatitis B virus (HBV) reactivation was observed (n = 4). Interestingly, the investigation found that two patients in the combined group, experienced elevated HBV DNA levels, however, without liver enzyme abnormalities and liver symptoms.
Although the study comprises small sample, it gives the basis to conduct further studies to elucidate how combined therapies can improve outcomes in AA, such as AU patients non-responding to monotherapy alone as well as characterization of side effects. The substitution of systemic for intralesional corticosteroids combined with JAK inhibitors or the response to newer JAK inhibitors is yet to be elucidated.
Author contributions
The author confirms being the sole contributor of this work and has approved it for publication.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Strazzulla LC, Wang EHC, Avila L, Sicco KL, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. (2018) 78:1–12. doi: 10.1016/j.jaad.2017.04.1141
2. Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol. (1999) 40(2 Pt 1):242–6. doi: 10.1016/s0190-9622(99)70195-7
3. Olsen EA, Roberts J, Sperling L, Tosti A, Shapiro J, McMichael A, et al. Objective outcome measures: collecting meaningful data on alopecia areata. J Am Acad Dermatol. (2018) 79:470–8. e3. doi: 10.1016/j.jaad.2017.10.048
4. Ray M, Swallow E, Gandhi K, Carley C, Sikirica V, Wang T, et al. Healthcare utilization and costs among US adolescents with alopecia areata. J Health Econ Outcomes Res. (2022) 9:11–8. doi: 10.36469/001c.36229
5. Lee HH, Gwillim E, Patel KR, Hua T, Rastogi S, Ibler E, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. (2020) 82:675–82. doi: 10.1016/j.jaad.2019.08.032
6. Wang H, Pan L, Wu Y. Epidemiological trends in alopecia areata at the global, regional, and national levels. Front Immunol. (2022) 13:874677. doi: 10.3389/fimmu.2022.874677
7. Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of Illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. (2020) 20:S62–8. doi: 10.1016/j.jisp.2020.05.007
8. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. (2015) 8:397–403. doi: 10.2147/CCID.S53985
9. Ghanizadeh A. Comorbidity of psychiatric disorders in children and adolescents with alopecia areata in a child and adolescent psychiatry clinical sample. Int J Dermatol. (2008) 47:1118–20. doi: 10.1111/j.1365-4632.2008.03743.x
10. Li SJ, Mostaghimi A, Tkachenko E, Huang KP. Association of out-of-pocket health care costs and financial burden for patients with alopecia areata. JAMA Dermatol. (2019) 155:493–4. doi: 10.1001/jamadermatol.2018.5218
11. Huang KP, Mullangi S, Guo Y, Qureshi AA. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol. (2013) 149:789–94. doi: 10.1001/jamadermatol.2013.3049
12. Peloquin L, Castelo-Soccio L. Alopecia areata: an update on treatment options for children. Paediatr Drugs. (2017) 19:411–22. doi: 10.1007/s40272-017-0239-z
13. Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. (2014) 134:2988–90. doi: 10.1038/jid.2014.260
14. Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. (2015) 14:81–9. doi: 10.1016/j.autrev.2014.10.014
15. Betz RC, Petukhova L, Ripke S, Huang H, Menelaou A, Redler S, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. (2015) 6:5966. doi: 10.1038/ncomms6966
16. Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, et al., Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. (2010) 466:113–7. doi: 10.1038/nature09114
Keywords: alopecia areata, JAK inhibitor, tofacitinib, corticosteroids, hair loss
Citation: Valdebran M (2023) Editorial: Advances in evaluation and management of hair loss disorders. Front. Med. 10:1131286. doi: 10.3389/fmed.2023.1131286
Received: 24 December 2022; Accepted: 10 January 2023;
Published: 20 January 2023.
Edited and reviewed by: Robert Gniadecki, University of Alberta, Canada
Copyright © 2023 Valdebran. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Manuel Valdebran, 
dmFsZGVicmFuJiN4MDAwNDA7bXVzYy5lZHU=